...
首页> 外文期刊>Leukemia Research: A Forum for Studies on Leukemia and Normal Hemopoiesis >Differential regulation of 11beta-hydroxysteroid dehydrogenase-1 by dexamethasone in glucocorticoid-sensitive and -resistant childhood lymphoblastic leukemia.
【24h】

Differential regulation of 11beta-hydroxysteroid dehydrogenase-1 by dexamethasone in glucocorticoid-sensitive and -resistant childhood lymphoblastic leukemia.

机译:地塞米松在糖皮质激素敏感性和耐药性儿童淋巴细胞白血病中对11β-羟类固醇脱氢酶-1的差异调节。

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

Glucocorticoid therapy forms a crucial first-line treatment for childhood acute lymphoblastic leukemia (ALL). However, glucocorticoid resistance is a therapeutic problem with an unclear molecular mechanism. 11beta-Hydroxysteroid dehydrogenase-1 (11beta-HSD1) is expressed in glucocorticoid target tissue, where it regenerates active glucocorticoids from inert 11keto-glucocorticoids, amplifying intracellular glucocorticoid levels. Here, we show 11beta-HSD1 expression in leukemic cells from ALL patients (n=14). 11beta-HSD1 was differentially regulated by glucocorticoids between glucocorticoid-sensitive and -resistant ALL cells. Dexamethasone increased 11beta-HSD1 mRNA levels in glucocorticoid-sensitive ALL cells, but decreased levels in the resistant group. Our data suggest that differential induction of 11beta-HSD1 contributes to the glucocorticoid sensitivity in leukemia.
机译:糖皮质激素治疗是儿童急性淋巴细胞白血病(ALL)的关键一线治疗。然而,糖皮质激素抵抗是一个尚不清楚分子机制的治疗问题。 11beta-羟基类固醇脱氢酶-1(11beta-HSD1)在糖皮质激素靶组织中表达,从惰性11酮-糖皮质激素中再生活性糖皮质激素,放大细胞内糖皮质激素水平。在这里,我们显示了来自所有患者(n = 14)的白血病细胞中的11beta-HSD1表达。 11beta-HSD1由糖皮质激素敏感和耐药的ALL细胞之间的糖皮质激素差异调节。地塞米松增加了糖皮质激素敏感的ALL细胞的11beta-HSD1 mRNA水平,但耐药组水平降低。我们的数据表明,11beta-HSD1的差异诱导有助于白血病中糖皮质激素的敏感性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号